Erythrocyte pyruvate kinase activation in red cell disorders.
Current opinion in hematology（2023）
摘要
Preclinical and clinical evidence indicate that pyruvate kinase activators represent new therapeutic option in hemoglobinopathies or SCD. Other red cell disorders such as hereditary spherocytosis or hereditary anaemias characterized by defective erythropoiesis might represent additional areas to investigate the therapeutic impact of pyruvate kinase activators.
更多查看译文
关键词
mitapivat etavopivat,pyruvate kinase activators,sickle cell disease,thalassemia
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要